The final study report will be sent directly to your treating oncologist, detailing the testing protocol used, drugs or combination therapies tested, and therapeutic response of each group of mouse cohorts over time, measured in terms of tumor volume. It will include actual MRI images of tumor size as well as detailed histology images of structural cellular changes observed during the study. Armed with Certis Oncology Intelligence™, your care team will have highly predictive drug response data that can bring greater certainty to treatment decisions.1-4 View a sample report.

Das Thakur, M., Salangsang, F., Landman, A. et al. Modelling Vemurafenib Resistance in Melanoma Reveals a Strategy to Forestall Drug ResistanceNature. 2013; 494(7436): 251–255.
Walters DM, Stokes JB, Adair SJ, et al. Clinical, Molecular and Genetic Validation of a Murine Orthotopic Xenograft Model of Pancreatic Adenocarcinoma Using Fresh Human SpecimensPLoS One. 2013;8(10): e77065.
Killion JJ, Radinsky R, Fidler IJ. Orthotopic Models are Necessary to Predict Therapy of Transplantable Tumors in MiceCancer Metastasis Rev. 1998-1999;17(3):279–284.
2013;8(10): e77065.
Qiu W, Su GH. Development of Orthotopic Pancreatic Tumor Mouse ModelsMol Biol. 2013; 980: 215-223.